Abstract

ABSTRACTObjectives: Our aim of this study is to compare the effect of Dexmedetomidine versus placebo for patients with cerebral protection during intracranial procedures.Methods: Rev.Man 5.1 and Stata 11.0 software is used for this study to make analysis, and use a fixed-effects model (the Mantel-Haenszel method) or a random-effects model (the DerSimonian and Laird method) to merge or aggregate the weighted mean difference (WMD) or risk ratio (RR) and its 95% confidence intervals (CI) of included studies.Results: Nine studies involving 404 patients with cerebral protection during intracranial procedures (experimental group: 202; control group: 202) were performed in this study. Significant differences of MAP > 100 mmHg(RR = 0.45, 95%CI = 0.29 to 0.69, P < 0.05), MAP< 60 mmHg (RR = 0.66, 95%CI = 0.43 to 1.00, P = 0.05), MAP when extubation (WMD = -12.57, 95%CI = -16.31 to −8.83, P < 0.05) and heart rate when extubation (WMD = -22.79, 95%CI = -30.57 to −15.01, P < 0.05) were observed between the two groups. There are no significant differences were found in HR > 100 bpm (RR = 0.52, 95%CI = 0.22 to 1.19, P > 0.05) and HR< 50 bpm (RR = 0.86, 95%CI = 0.31 to 2.38, P > 0.05) between the two groups.Conclusions: Our results suggested that the efficacy of Dexmedetomidine for patients with cerebral protection during intracranial procedures is better than placebo treatment.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call